Hospital de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain.
J Clin Microbiol. 2010 Oct;48(10):3703-7. doi: 10.1128/JCM.00144-10. Epub 2010 Jul 28.
Clarithromycin is one of the antibiotics used for the treatment of Helicobacter pylori infections, and clarithromycin resistance is the most important factor when it comes to predicting eradication failure. The present study analyzed H. pylori isolates for the presence of 23S rRNA gene mutations and determined the risk factors associated with resistance among H. pylori isolates collected in Madrid, Spain, in 2008. We studied 118 H. pylori strains isolated from the same number of patients. A total of 76.3% of the patients were born in Spain, 52.7% were children, 20.3% had previously been treated, and 66.1% were female. Clarithromycin resistance was determined by Etest. H. pylori strains were considered resistant if the MIC was ≥1 mg/liter. DNA extraction was carried out by use of the NucliSens easyMAG platform with NucliSens magnetic extraction reagents (bioMérieux). The DNA sequences of the 23S rRNA genes of clarithromycin-resistant and -sensitive strains were determined to identify specific point mutations. The vacA genotype and cagA status were determined by PCR. We found that 42 (35.6%) strains were resistant to clarithromycin by Etest. Etest results were confirmed by detection of the presence of point mutations in 34 (88.1%) of these strains. Eight H. pylori strains were resistant to clarithromycin by Etest but did not have a point mutation in the 23S rRNA gene. Mutation at A2143G was found in 85.3% of the strains, mutation at A2142G in 8.8%, and mutation at T2182C in 5.9%. Dual mutations were found in 8.8% of the strains. H. pylori clarithromycin-resistant strains were strongly associated with pediatric patients, with patients born in Spain, and with patients who had previously been treated (P ≤ 0.02). In addition, H. pylori strains resistant to clarithromycin more frequently presented the vacA s2/m2 genotype and were more likely to be cagA negative than susceptible strains (39.1% and 11.2%, respectively; P value < 0.001). We concluded that, in the present study, H. pylori clarithromycin-resistant strains are more frequently found in children, in patients mostly born in Spain, and in individuals who were previously treated for H. pylori infection and that these individuals are more likely colonized with a less virulent H. pylori strain.
克拉霉素是治疗幽门螺杆菌感染的抗生素之一,克拉霉素耐药性是预测根除失败的最重要因素。本研究分析了来自西班牙马德里 2008 年收集的幽门螺杆菌分离株中 23S rRNA 基因突变,并确定了与幽门螺杆菌分离株耐药相关的危险因素。我们研究了 118 株从相同数量的患者中分离出的幽门螺杆菌株。共有 76.3%的患者在西班牙出生,52.7%为儿童,20.3%曾接受过治疗,66.1%为女性。采用 Etest 法测定克拉霉素耐药性。如果 MIC≥1mg/L,则认为幽门螺杆菌株耐药。使用 NucliSens easyMAG 平台和 NucliSens 磁性提取试剂(bioMérieux)提取 DNA。通过聚合酶链反应(PCR)确定 vacA 基因型和 cagA 状态。我们发现,通过 Etest 法,有 42(35.6%)株对克拉霉素耐药。通过检测 34 株(88.1%)这些菌株中特定点突变的存在,证实了 Etest 结果。8 株幽门螺杆菌株对克拉霉素耐药,但 23S rRNA 基因无点突变。我们发现,85.3%的菌株存在 A2143G 突变,8.8%的菌株存在 A2142G 突变,5.9%的菌株存在 T2182C 突变。8.8%的菌株存在双重突变。与儿童、西班牙出生和曾接受过治疗的患者相比,幽门螺杆菌克拉霉素耐药株更为常见(P≤0.02)。此外,与敏感株相比,克拉霉素耐药的幽门螺杆菌株更常出现 vacA s2/m2 基因型,且更可能为 cagA 阴性(分别为 39.1%和 11.2%;P 值<0.001)。我们的结论是,在本研究中,儿童、西班牙出生的患者和曾接受过幽门螺杆菌感染治疗的患者中更常发现幽门螺杆菌克拉霉素耐药株,且这些患者更可能定植于毒力较弱的幽门螺杆菌株。